NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH
AFRICA




PRESS RELEASE



GenSight Biologics Announces the Closing of the
Company’s c. €4 Million Private Placement

Paris, France, July 3, 2025, 9:00 pm CET – GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN:
FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today
announced the closing of its EUR 3,908,715.39 private placement (the “Private Placement”).
The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the
"Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025
(ISIN FR0013183985/SIGHT).
The issuance of:
(i) The 1,850,000 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to
subscribe to 1,850,000 additional ordinary shares (the "Pre-Funded Warrant Shares"); and
(ii) The 23,101,267 warrants (the "Offered Investor Warrants") giving the right to subscribe to
23,101,267 additional ordinary shares (the "Investor Warrant Shares")
is expected to take place tomorrow, July 4, 2025.
The Offered Investor Warrants will be admitted to trading on the Euronext Growth market in Paris
("Euronext Growth Paris") on July 7, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded
Warrants will not be admitted to trading on any venue.
Part of the proceeds, EUR 0.7 million, has been used for the repayment in principal on the convertible
bonds held by Heights Capital through offset against their subscription.
Maxim Group, LLC acted as sole placement agent for the Private Placement in the United States,
pursuant to an agreement entered into with the Company.


Risk factors

The Company draws the attention of the public to the risk factors relating to the Company and its business
described in its 2024 Universal Registration Document, as amended by the Information Document published
by the Company on July 1st, 2025, both of which are available free of charge on the Company's website
(https://www.gensight-biologics.com/).


Contacts

GenSight Biologics
Chief Financial Officer
Jan Eryk Umiastowski
jeumiastowski@gensight-biologics.com




1
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH
AFRICA

About GenSight Biologics S.A.
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing
innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence
(MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.
GenSight Biologics’ lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber
Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens
and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are
designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a
sustainable functional visual recovery.

Disclaimer
Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South
Africa. This press release and the information contained herein do not contain or constitute an offer to
subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United
States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The
securities referred to herein have not been and will not be registered under the Securities Act, or under the
securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold
in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and in compliance with the securities laws of any state or any
other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in
the United States of America.

The distribution of this press release may be subject to legal or regulatory restrictions in certain countries.
Persons in possession of this press release should inform themselves of and observe any local restrictions.
The information contained herein is subject to change without notice.

Forward-Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical
facts, included in this press release are forward-looking statements. These forward-looking statements include,
but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds
of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and
prospects of the Company. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future”
or similar expressions are intended to identify forward-looking statements. These forward-looking statements
are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be
given that the proposed securities offering discussed above will be consummated on the terms described or
at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors,
many of which are beyond the control of the Company, including, without limitation, market conditions, failure
of customary closing conditions and the risk factors and other matters set forth in the filings the Company
makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-
looking statements, whether because of new information, future events or otherwise, except as may be
required by law.




2